Theralase completes enrollment in Phase II BCG-unresponsive NMIBC bladder cancer study

Theralase Technologies completed enrollment in its Phase II BCG-unresponsive non-muscle invasive bladder cancer study, enrolling 96 patients with 87 having completed the trial and 9 under assessment. The company is compiling data to support NDS and NDA submissions to Health Canada and the FDA, with marketing decisions expected in 2027.

Detected & updated continuously · Source: Nebula